UK charity to fund Lucentis court case

25 July 2007

The Royal National Institute of Blind People (RNIB), a UK charity, has announced it will support the legal battle by an 84-year old man to have access to Swiss drug major Novartis' Lucentis (ranibizumab). The decision follows the controversy over a ruling by the National Institute for Health and Clinical Excellence to recommend that the drug should only be made available to National Health Service patients in restricted circumstances (Marketletter June 25).

Steve Winyard, an RNIB spokesman, told the BBC that the Oxfordshire Primary Care Trust, which claims to consider cases individually, had yet to authorize the drug to a patient.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight